Terms: = Pancreatic cancer AND PALB2, ENSG00000083093, 79728
175 results:
1. pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection.
Brozos-Vázquez E; Toledano-Fonseca M; Costa-Fraga N; García-Ortiz MV; Díaz-Lagares Á; Rodríguez-Ariza A; Aranda E; López-López R
Cancer Treat Rev; 2024 Apr; 125():102719. PubMed ID: 38490088
[TBL] [Abstract] [Full Text] [Related]
2. A Somatic BRCA2-Mutated pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOX.
Jamison JK; May MS; Raufi AG; Luk L; Wong W; Mundi PS; Manji GA
Oncologist; 2024 Apr; 29(4):350-355. PubMed ID: 38394390
[TBL] [Abstract] [Full Text] [Related]
3. Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan.
Cheng SM; Su YY; Chiang NJ; Wang CJ; Chao YJ; Huang CJ; Tsai HJ; Chen SH; Chang CY; Tsai CR; Li YJ; Yen CJ; Chuang SC; Chang JS; Shan YS; Hwang DY; Chen LT
J Biomed Sci; 2024 Feb; 31(1):21. PubMed ID: 38350919
[TBL] [Abstract] [Full Text] [Related]
4. Targeting BRCA and palb2 in pancreatic cancer.
Anbil S; Reiss KA
Curr Treat Options Oncol; 2024 Mar; 25(3):346-363. PubMed ID: 38311708
[TBL] [Abstract] [Full Text] [Related]
5. Cost-Effectiveness Analysis of Screening for pancreatic cancer Among High-Risk Populations.
Peters MLB; Eckel A; Seguin CL; Davidi B; Howard DH; Knudsen AB; Pandharipande PV
JCO Oncol Pract; 2024 Feb; 20(2):278-290. PubMed ID: 38086003
[TBL] [Abstract] [Full Text] [Related]
6. Association of pancreatic Adenocarcinoma Location With DNA Damage Response Status and Response to Platinum-Based Therapy.
Micaily I; Blais EM; Carhart R; Lam S; Cohen SJ; Cannaday SJ; Halverson D; Matrisian LM; DeArbeloa P; Thach D; Petricoin E; Pishvaian MJ; Lavu H; Yeo CJ; Mallick AB
JCO Precis Oncol; 2023 Sep; 7():e2200648. PubMed ID: 38085059
[TBL] [Abstract] [Full Text] [Related]
7. Multiomic Characterization Reveals a Distinct Molecular Landscape in Young-Onset pancreatic cancer.
Ogobuiro I; Baca Y; Ribeiro JR; Walker P; Wilson GC; Gulhati P; Marshall JL; Shroff RT; Spetzler D; Oberley MJ; Abbott DE; Kim HJ; Kooby DA; Maithel SK; Ahmad SA; Merchant NB; Xiu J; Hosein PJ; Datta J
JCO Precis Oncol; 2023 Sep; 7():e2300152. PubMed ID: 37944072
[TBL] [Abstract] [Full Text] [Related]
8. NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and pancreatic, Version 2.2024.
Daly MB; Pal T; Maxwell KN; Churpek J; Kohlmann W; AlHilli Z; Arun B; Buys SS; Cheng H; Domchek SM; Friedman S; Giri V; Goggins M; Hagemann A; Hendrix A; Hutton ML; Karlan BY; Kassem N; Khan S; Khoury K; Kurian AW; Laronga C; Mak JS; Mansour J; McDonnell K; Menendez CS; Merajver SD; Norquist BS; Offit K; Rash D; Reiser G; Senter-Jamieson L; Shannon KM; Visvanathan K; Welborn J; Wick MJ; Wood M; Yurgelun MB; Dwyer MA; Darlow SD
J Natl Compr Canc Netw; 2023 Oct; 21(10):1000-1010. PubMed ID: 37856201
[TBL] [Abstract] [Full Text] [Related]
9. Association of Glycated Hemoglobin With a Risk of pancreatic cancer in High-Risk Individuals Based on Genetic and Family History.
Wu BU; Chen Q; Moon BH; Lustigova E; Nielsen EG; Alvarado M; Ahmed SA
Clin Transl Gastroenterol; 2024 Jan; 15(1):e00650. PubMed ID: 37800692
[TBL] [Abstract] [Full Text] [Related]
10. Deciphering the Pathways to PARP Sensitivity in pancreatic cancer.
Tsang ES; Gallinger S
Clin Cancer Res; 2023 Dec; 29(24):5005-5007. PubMed ID: 37787975
[TBL] [Abstract] [Full Text] [Related]
11. Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in pancreatic Acinar Cell Carcinoma.
Mandelker D; Marra A; Zheng-Lin B; Selenica P; Blanco-Heredia J; Zhu Y; Gazzo A; Wong D; Yelskaya Z; Rai V; Somar J; Ostafi S; Mehta N; Yang C; Li Y; Brown DN; da Silva EM; Pei X; Linkov I; Terraf P; Misyura M; Ceyhan-Birsoy O; Ladanyi M; Berger M; Pareja F; Stadler Z; Offit K; Riaz N; Park W; Chou J; Capanu M; Koehler M; Rosen E; O'Reilly EM; Reis-Filho JS
J Clin Oncol; 2023 Nov; 41(33):5151-5162. PubMed ID: 37607324
[TBL] [Abstract] [Full Text] [Related]
12. Screening Practices for Breast and Nonbreast cancers in High-Risk Mutation Carriers.
Coogan AC; Lunt LG; Keshwani SS; Sandhu O; Zhang Y; O'Donoghue C; Madrigrano A
J Surg Res; 2023 Nov; 291():388-395. PubMed ID: 37516046
[TBL] [Abstract] [Full Text] [Related]
13. The Clinical Implications of Reversions in Patients with Advanced pancreatic cancer and Pathogenic Variants in BRCA1, BRCA2, or palb2 after Progression on Rucaparib.
Brown TJ; Yablonovitch A; Till JE; Yen J; Kiedrowski LA; Hood R; O'Hara MH; Teitelbaum U; Karasic TB; Schneider C; Carpenter EL; Nathanson K; Domchek SM; Reiss KA
Clin Cancer Res; 2023 Dec; 29(24):5207-5216. PubMed ID: 37486343
[TBL] [Abstract] [Full Text] [Related]
14. Geographical, ethnic, and genetic differences in pancreatic cancer predisposition.
Liew SZH; Ng KW; Ishak NDB; Lee SY; Zhang Z; Chiang J; Ngeow JYY
Chin Clin Oncol; 2023 Jun; 12(3):27. PubMed ID: 37417291
[TBL] [Abstract] [Full Text] [Related]
15. Tumor Mutational Burden in Real-World Patients With pancreatic cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness.
Quintanilha JCF; Storandt MH; Graf RP; Li G; Keller R; Lin DI; Ross JS; Huang RSP; Schrock AB; Oxnard GR; Chakrabarti S; Mahipal A
JCO Precis Oncol; 2023 Jul; 7():e2300092. PubMed ID: 37410975
[TBL] [Abstract] [Full Text] [Related]
16. A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic pancreatic cancer.
Chen KT; Madison R; Moore J; Jin D; Fleischmann Z; Newberg J; Schrock A; Bhardwaj N; Lofgren KT; He J; Frampton G; Hegde P; Fabrizio D; Pishvaian MJ; Ebot E; Singhi A; Sokol E
Oncologist; 2023 Aug; 28(8):691-698. PubMed ID: 37354528
[TBL] [Abstract] [Full Text] [Related]
17. Comparative Genomic Analysis of pancreatic Acinar Cell Carcinoma (PACC) and pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC.
Florou V; Elliott A; Bailey MH; Stone D; Affolter K; Soares HP; Nevala-Plagemann C; Scaife C; Walker P; Korn WM; Lou E; Shroff RT; Hosein PJ; Garrido-Laguna I
Clin Cancer Res; 2023 Sep; 29(17):3408-3417. PubMed ID: 37266563
[TBL] [Abstract] [Full Text] [Related]
18. Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing pancreatic cancer Surveillance.
Katona BW; Klute K; Brand RE; Everett JN; Farrell JJ; Hawthorne K; Kaul V; Kupfer SS; Paiella S; Simeone DM; Sussman DA; Zogopoulos G; Lucas AL; Kastrinos F;
Cancer Prev Res (Phila); 2023 Jun; 16(6):343-352. PubMed ID: 37259800
[TBL] [Abstract] [Full Text] [Related]
19. Risk of Syndrome-Associated cancers Among First-Degree Relatives of Patients With pancreatic Ductal Adenocarcinoma With Pathogenic or Likely Pathogenic Germline Variants.
Chen X; Meyer MA; Kemppainen JL; Horibe M; Chandra S; Majumder S; Petersen GM; Rabe KG
JAMA Oncol; 2023 Jul; 9(7):955-961. PubMed ID: 37200008
[TBL] [Abstract] [Full Text] [Related]
20. Patients with deleterious germline mutations: A heterogeneous population for pancreatic cancer screening?
Roch AM; Kim RC; Nguyen TK; House MG; Zyromski NJ; Nakeeb A; Schmidt CM; Ceppa EP
J Surg Oncol; 2023 Aug; 128(2):289-294. PubMed ID: 37083062
[TBL] [Abstract] [Full Text] [Related]
[Next]
